Propranolol as an alternative treatment option for pediatric lymphatic malformation

Tohoku Journal of Experimental Medicine

Volumn 229, Issue 1, 2012, Pages 61-66

  Ozeki, Michio ^a   Kanda, Kaori ^a   Kawamoto, Norio ^a   Ohnishi, Hidenori ^a   Fujino, Akihiro ^b   Hirayama, Masahiro ^c   Kato, Zenichiro ^a   Azuma, Eiichi ^c   Fukao, Toshiyuki ^a   Kondo, Naomi ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta blocker; Lymphangioma; Lymphatic malformation; Propranolol; Vascular endothelial growth factor

Indexed keywords

PICIBANIL; PROPRANOLOL; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INFANT; JAPANESE; LYMPHATIC MALFORMATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; PRESCHOOL CHILD; PROTEIN FAMILY; RANK SUM TEST; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; WILCOXON SIGNED RANKS TEST;

ADMINISTRATION, ORAL; HUMANS; INFANT; JAPAN; LYMPHANGIOMA; MAGNETIC RESONANCE IMAGING; PROPRANOLOL; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84873055186     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.229.61     Document Type: Article

References (12)

1. Alitalo, K. & Carmeliet, P. (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell, 1, 219-227.
2. Bingham, M.M., Saltzman, B., Vo, N.J. & Perkins, J.A. (2012) Propranolol reduces infantile hemangioma volume and vessel density. Otolaryngol. Head Neck Surg., 147, 338-344.
3. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev., 25, 581-611.
4. Itakura, E., Yamamoto, H., Oda, Y., Furue, M. & Tsuneyoshi, M. (2009) VEGF-C and VEGFR-3 in a series of lymphangiomas: is superficial lymphangioma a true lymphangioma? Virchows Arch., 454, 317-325.
5. Léauté-Labrèze, C., Dumas, E., Hubiche, T., Boralevi, F., Thambo, J.B. & Taïeb, A. (2008) Propranolol for severe hemangiomas of infancy. N. Engl. J. Med., 358, 2649-2651.
6. Leboulanger, N., Garel, C., Borde, I.T., Garabedian, E.N. & Denoyelle, F. (2011) Propranolol therapy for hemorrhagic lymphangioma of the tongue. Arch. Otolaryngol. Head Neck Surg., 137, 813-815.
7. Marler, J.J. & Mulliken, J.B. (2005) Current management of hemangiomas and vascular malformations. Clin. Plast. Surg, 32, 99-116.
8. Ozeki, M., Fukao, T. & Kondo, N. (2011) Propranolol for intractable diffuse lymphangiomatosis. N. Engl. J. Med., 364, 1380-1382.
9. Peridis, S., Pilgrim, G., Athanasopoulos, I. & Parpounas, K. (2011) A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int. J. Pediatr. Otorhinolaryngol., 75, 455-460.
10. Sidle, D.M., Maddalozzo, J., Meier, J.D., Cornwell, M., Stellmach, V. & Crawford, S.E. (2005) Altered pigment epitheliumderived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence. Arch. Otolaryngol. Head Neck Surg., 131, 990-995.
11. Storch, C.H. & Hoeger, P.H. (2010) Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br. J. Dermatol., 163, 269-274.
12. Wiegand, S., Eivazi, B., Barth, P.J., von Rautenfeld, D.B., Folz, B.J., Mandic, R. & Werner, J.A. (2008) Pathogenesis of lymphangiomas. Virchows Arch., 453, 1-8.